Background Current clinical phenotyping of musculoskeletal pain provides very limited
evidence‐based support to personalized medicine. This paper discusses the potential of …

Over 25 years ago, Mitchell Max proposed that “more effective, less toxic treatments” could
be developed by targeting the specific pathophysiologic mechanisms that account for …

Currently available treatments for neuropathic pain fail in roughly half of the patients–and it
is impossible to predict which treatments will help patients. Stratification of neuropathic pain …

The discussed trials show the importance of the development of an individualized pain
therapy. Up to now, no clinical trial has prospectively used the sensory phenotype as an …

Neuropathic pain (NeuP) is quite challenging to treat. The current evidence suggests that
between 6 and 8 patients need to be treated with first-line drugs such as voltage-gated …

Patients with the same neuropathic pain disorder may have completely different sensory
signs and symptoms yet receive the same medicinal treatment. New concepts suggest that …

In recent years, more and more effort has been invested in the identification of biomarkers
for the treatment of neuropathic pain. Given the fact that many clinical trials on development …

Physical therapists use a number of tools for pain management, including exercise,
education, thermal and electrical agents, and orthopedic manual therapy (OMT). Orthopedic …

Background. In recent years, several published articles have demonstrated that quantitative
sensory testing (QST) is useful in the analysis of musculoskeletal pain disorders. Based on …

The concept of mechanism-based treatment of chronic pain is based on the belief that
specific signs and symptoms reflect the mechanisms underlying pain generation and pain …